310 related articles for article (PubMed ID: 34887852)
1. Dual Targeting by Inhibition of Phosphoinositide-3-Kinase and Mammalian Target of Rapamycin Attenuates the Neuroinflammatory Responses in Murine Hippocampal Cells and Seizures in C57BL/6 Mice.
Vyas P; Tulsawani R; Vohora D
Front Immunol; 2021; 12():739452. PubMed ID: 34887852
[TBL] [Abstract][Full Text] [Related]
2. Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys.
Shi H; Leonhard WN; Sijbrandi NJ; van Steenbergen MJ; Fens MHAM; van de Dikkenberg JB; Toraño JS; Peters DJM; Hennink WE; Kok RJ
J Control Release; 2019 Jan; 293():113-125. PubMed ID: 30472374
[TBL] [Abstract][Full Text] [Related]
3. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
4. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
5. Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release.
Russo E; Andreozzi F; Iuliano R; Dattilo V; Procopio T; Fiume G; Mimmi S; Perrotti N; Citraro R; Sesti G; Constanti A; De Sarro G
Brain Behav Immun; 2014 Nov; 42():157-68. PubMed ID: 24998197
[TBL] [Abstract][Full Text] [Related]
6. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures.
Yang MT; Lin YC; Ho WH; Liu CL; Lee WT
J Neuroinflammation; 2017 Jan; 14(1):15. PubMed ID: 28109197
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
8. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of scoparone on pilocarpine (Pilo)-induced seizures in mice.
Xia J; Li CY; Wang H; Zhang QM; Han ZM
Biomed Pharmacother; 2018 Jan; 97():1501-1513. PubMed ID: 29793313
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
11. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury.
Campolo M; Casili G; Lanza M; Filippone A; Cordaro M; Ardizzone A; Scuderi SA; Cuzzocrea S; Esposito E; Paterniti I
J Cell Mol Med; 2021 Aug; 25(16):7855-7866. PubMed ID: 34245104
[TBL] [Abstract][Full Text] [Related]
12. Loss of Protection by Antiepileptic Drugs in Lipopolysaccharide-primed Pilocarpine-induced Status Epilepticus is Mediated via Inflammatory Signalling.
Vyas P; Tulsawani RK; Vohora D
Neuroscience; 2020 Aug; 442():1-16. PubMed ID: 32592825
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by lipopolysaccharide challenge in rats.
Guden DS; Temiz-Resitoglu M; Senol SP; Kibar D; Yilmaz SN; Tunctan B; Malik KU; Sahan-Firat S
Can J Physiol Pharmacol; 2021 Sep; 99(9):921-934. PubMed ID: 33641344
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
15. HMGB1/PI3K/Akt/mTOR Signaling Participates in the Pathological Process of Acute Lung Injury by Regulating the Maturation and Function of Dendritic Cells.
Li R; Zou X; Huang H; Yu Y; Zhang H; Liu P; Pan S; Ouyang Y; Shang Y
Front Immunol; 2020; 11():1104. PubMed ID: 32636835
[No Abstract] [Full Text] [Related]
16. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D
Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
[TBL] [Abstract][Full Text] [Related]
18. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
20. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
